Answers are grounded in this paper and cite their sources.
Lung cancer is a common malignancy in many countries and places a substantial mortality burden on public health systems worldwide. Despite recent advances in diagnosis and treatment, standard therapies often cause severe adverse effects and lead to drug resistance. These limitations highlight the need for safer and more effective treatment options. Fucoidan, a natural sulfated polysaccharide derived from marine brown algae, exhibits antitumor, antifibrotic, anti-inflammatory, and antioxidant activities, supporting its potential biomedical applications. Although interest in its biological activities has grown, research specifically addressing its therapeutic role in lung cancer remains limited. The molecular mechanisms underlying its effects on lung cancer cells are also incompletely understood. This review examines the pharmacological effects of fucoidan against lung cancer and evaluates its potential as an adjuvant therapeutic agent.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: